Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2025

Conditions
Chronic Spontaneous Urticaria
Interventions
BIOLOGICAL

LP-003

Liquid in vial

BIOLOGICAL

Placebo

Liquid in vial

BIOLOGICAL

Omalizumab

Liquid in vial

Trial Locations (16)

Unknown

RECRUITING

Beijing Friendship Hospital, Capital Medical University, Beijing

RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

RECRUITING

Peking University Third Hospital, Beijing

RECRUITING

The First Affiliated Hospital of China Medical University, Beijing

RECRUITING

The First Hospital of Peking University, Beijing

RECRUITING

The First Affiliated Hospital of PLA Army Medical University, Chongqing

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

RECRUITING

Dermatology Hospital of Southern Medical University, Guangzhou

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

The Second XiangYa Hospital of Central South University, Changsha

RECRUITING

Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

RECRUITING

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

RECRUITING

Shanghai Skin Disease Hospital, Shanghai

RECRUITING

the Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Longbio Pharma

INDUSTRY